BACKGROUND Coronary artery disease (CAD) has substantial heritability and a polygenic architecture. However, the
A s coronary artery disease (CAD) is the leading cause of morbidity and mortality worldwide, early identification of individuals who are at high risk of CAD is essential for primary prevention.
As the heritability of CAD has been estimated to be 40% to 60%, comprehensive information on genetic susceptibility could contribute importantly to CAD risk stratification (1, 2) .
Although family history has long been identified as a risk factor for CAD, elucidation of the genetic architecture of CAD has advanced substantially only during the past decade with the advent of genomewide association studies. Results from these assumption-free surveys across the genome have laid foundations for developing genomic risk scores (GRS) in the estimation of an individual's underlying genomic risk (3) (4) (5) (6) (7) (8) (9) . Furthermore, because GRS are based on germline DNA, they are quantifiable in early life, at or before birth. Hence, they offer the potential for early risk screening and primary prevention before other conventional risk factors become informative.
Due to several inter-related factors, however, previous GRS for CAD have been unable to provide comprehensive assessment of the potential of using genomic information in CAD risk prediction.
First, because previously published GRS have utilized only genetic variants of genome-wide significance (4, 5, 8) or involved genotyping arrays that focused only on pre-selected loci (3), they have not fully utilized genome-wide variation, preventing accurate estimation of the relative contribution of each genetic variant to CAD risk. Second, because previous studies mass index [BMI] , diabetes, family history, and high cholesterol) on different genomic risk backgrounds, with the aim of delineating event rates across age, sex, clinical risk factors, and genomic risk score strata to identify individuals who are more likely to benefit from earlier and more intensive therapies. Finally, to assess the potential therapeutic implications of genomic risk scores, we tested the impact of blood pressure and lipid-lowering medication on the performance of the metaGRS. 
Death registries include all deaths in the United
Kingdom until January 2016, with both primary and contributory causes of death coded in ICD-10.
CAD was defined as fatal or nonfatal myocardial infarction (MI) cases, percutaneous transluminal coronary angioplasty (PTCA), or coronary artery bypass grafting (CABG). The age of event in prevalent cases was determined by self-reported age and calculated age based on the earliest hospital record for the event; if both self-reported age and calculated age were available, the smaller value was used. For incident cases, hospital and/or death records were used to determined age of event. Prevalent versus incident status was relative to the UKB enrollment assessment. In UKB self-reported data, cases were defined as having had a heart attack diagnosed by a doctor (data field #6150); "non-cancer illnesses that self-reported as heart attack" (data field #20002); or self-reported operation including PTCA, CABG, or triple heart bypass (data field #20004). In HES hospital episodes data and death registry data, MI was defined as hospital admission or cause of death due to ICD-9 410 to 412, or ICD-10 I21 to I24 or I25.2; CABG and PTCA were defined as hospital admission OPCS-4 K40 to K46, K49, K50.1, or K75.
We defined risk factors at the first assessment as follows: diabetes diagnosed by a doctor (field #2443), BMI (field #21001), current smoking (field #20116), hypertension, family history of heart disease, and high cholesterol. For hypertension we used an expanded definition including self-reported high blood pressure (either on blood pressure medication, data fields #6177, #6153; systolic blood pressure >140 mm Hg, fields #4080, #93; or diastolic blood pressure >90 mm Hg, data fields #4079, #94). For family history of heart disease, we considered history in any firstdegree relative (father, mother, sibling; fields Genotyping of UK Biobank participants was undertaken using a custom-built genome-wide array (the UK Biobank Axiom array) of w826,000 markers.
Genotyping was done in 2 phases. A total of 50,000 subjects were initially typed as part of the UK BiLEVE project (16) . The rest of the participants were genotyped using a slightly modified array. Imputation to w92 million markers was subsequently carried out using the Haplotype Reference Consortium (17) and UK10K/1000Genomes haplotype resource panels;
however, at the time of analysis, known issues existed with the imputation using the latter panel.
DATA PROCESSING AND QUALITY CONTROL. A detailed description is available in the Online
Appendix. Briefly, we adapted appropriate qualitycontrol procedures to the set of GWAS (genome-wide association study) summary statistics being utilized, filtering genetic variants for minor allele frequency,
Hardy-Weinberg equilibrium, and imputation quality using PLINK (18) . Population structure was controlled Values are mean AE SD or n (%). CAD ¼ coronary artery disease. 
RESULTS
The characteristics of the UKB subjects in the external validation set (N ¼ 482,629) are shown in Table 1 , (8) in the UKB external validation set is given in Figure 1 ,
showing that the metaGRS had substantially greater association with CAD risk in terms of hazard ratio (HR) as well as positive predictive value at any given sensitivity.
In the external UKB validation set, the metaGRS was accurate at classifying CAD cases versus non- other abbreviations as in Figure 1 . To investigate the potential role of the metaGRS in earlier life genetic screening, we compared the sex-stratified cumulative incidence of CAD across quintiles of the metaGRS (Figure 3) . In UKB men, we observed that CAD risk in the highest metaGRS quintile began exponentially increasing shortly after age 40 years, reaching a threshold of 10% cumulative risk by 61 years of age ( Figure 3) . By comparison, CAD risk for men in the lowest metaGRS quintile did not Table 1 . HR ¼ hazard ratio; other abbreviations as in Figure 1 .
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begin increasing until age 50 years, and on average, did not reach 10% by the censoring age of 75 years.
In UKB women, the metaGRS results were similar but delayed given the lower absolute CAD risk overall compared with men. For women in the highest metaGRS quintile, CAD risk began increasing at age 49 years and reached 10% at age 75 years, whereas women in the lowest metaGRS quintile were at extremely low levels of risk, reaching 2.5% CAD risk Dotted lines represent 95% CIs. GRS ¼ genomic risk score; HR ¼ hazard ratio; other abbreviations as in Figure 1 . 
DISCUSSION
In an analysis of almost 500,000 people in a prospective nationwide cohort study, we evaluated a combined genomic risk score (metaGRS) built from summary statistics of the largest previous genomewide association studies of CAD (Central Illustration).
We report a series of findings that substantially advance the concept of using genomic information to help stratify individuals for CAD risk in general populations, an approach that leverages the fixed nature of germline DNA over the life course to anticipate different lifelong trajectories of CAD risk.
First, our metaGRS achieved greater risk discrimination than previously published genomic risk scores based on selected SNPs (3-9). For example, we found The genomic score provides potential for risk screening early in life as well as complements conventional risk factors for coronary artery disease. In translating genomic risk scores, standardization in assay and data processing will be necessary but achievable, including in imputation (e.g., reference panel and quality control) and handling of population stratification (e.g., using a population-specific GRS distribution and/or adjustment of GRS directly).
We have made the metaGRS algorithm freely avail- (24) . Fourth, current GWAS sample sizes and imputation efficiencies are also limiting in that they introduce noise into GRS estimates. Our meta-score approach here addresses this to some extent; however, future large-scale cohorts will offer more powerful genomic scores.
Last, despite the metaGRS showing substantial CAD risk discrimination in individuals already on medication, we were also unable to assess the effect of medication versus nonmedication in individuals who are at high metaGRS risk, as without blind randomization, this analysis would be susceptible to reverse causation, with those on medication likely already at higher CAD risk.
CONCLUSIONS
The genomic score developed and evaluated in the present study strengthens the concept of using genomic information to stratify individuals for CAD risk in general populations and demonstrates the potential for genomic screening in early life to complement conventional risk prediction.
